Michelle Dawson posts

Post published on Twitter/X on 29 Mar 2022 06:13

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms
Open original post

Information about the link integrated into the post

Clinical trial

Joanne Kurtzberg, MD, The Marcus Foundation (2022). hCT-MSC Infusion in Adults With Autism Spectrum Disorder. ClinicalTrials.gov. Joanne Kurtzberg, MD.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Joanne Kurtzberg, MD, The Marcus Foundation (2022). hCT-MSC Infusion in Adults With Autism Spectrum Disorder. ClinicalTrials.gov. Joanne Kurtzberg, MD.

Publication date
24 Jan 2022
Identifier
NCT04484077
Authors
Joanne Kurtzberg, MD, The Marcus Foundation
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Joanne Kurtzberg, MD
Metadata source
clinicaltrials.gov

Abstract

The purpose of the study is to determine the safety and tolerability of a single intravenous dose of Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in adults with autism spectrum disorder (ASD). hCT-MSC is a cell product isolated from umbilical cord tissue. The cells from the cord tissue are processed and expanded in the laboratory and then infused intravenously in a single dose per participant. Participants will be ages 18-35 years, with ASD and a full-scale IQ \>70 without an identified genetic cause of autism. Participants will have an in-person baseline visit and remote follow up visits at 6 and 12 months. In addition to the primary endpoints evaluating safety, the study will evaluate changes in social communications skills after hCT-MSC administration.

Open source